KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Variations in the Natural History of High-Risk HPV Types Following HPV-16/18 Bivalent Vaccination in Females Aged 18-45 Years.

Qi Chen, Jiali Quan, Kongxin Zhu, Linchen Lan, Jiaoxi Lu, Linfeng Zhu, Bin Zhang, Guohua Zhong, Zhaofeng Bi, Shoujie Huang, Yingying Su, Lihui Wei, Youlin Qiao, Jun Zhang, Ting Wu, Ningshao Xia

Nat Commun 17(1) 1677

PMID41535287
PMCIDPMC12909933
DOI10.1038/s41467-026-68379-3
发表日期2026-01-14
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
KM panel re-extraction failed
摘要

摘要

Existing evidence regarding the impact of vaccination on the natural history of high-risk human papillomavirus (HPV) infections remains limited, understanding such effects is essential for optimizing cervical cancer screening in post-vaccination era. Using 10-year follow-up data from a phase 3 randomized trial of the Escherichia coli-produced HPV-16/18 bivalent vaccine (NCT01735006) and its extension study (NCT05045755, NCT04969445), we compared the spectra and natural history (persistence, clearance, and progression) of high-risk HPV infections between vaccinated and unvaccinated females aged 18-45 years. Data was analyzed using the Cox regression and the competing risk model. Our findings indicate that vaccination reduces the burden of HPV-16/18-associated lesions (HR = 0.12, p = 0.0041) primarily by preventing incident infections (HR = 0.45, p < 0.0001) and modifying the natural history of breakthrough infections (enhancing clearance: 98.5% vs. 93.8%, p < 0.0001; and attenuating progression: 1.5% vs. 6.2%, p = 0.0420). Conversely, the elevated burden of HPV-52-associated lesions (HR = 3.06, p = 0.0303) observed in the vaccine group stems mainly from altered natural history (reduced clearance: 90.3% vs. 97.9%, p = 0.0144; and increased progression: 9.7% vs. 2.1%, p = 0.0421), rather than an increase in incidence (HR = 1.09, p = 0.2669). In this work, the observed shifts in HPV infection profiles and natural history between vaccinated and unvaccinated populations suggest that cervical cancer screening recommendations may warrant adjustment for vaccinated individuals.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Fig. 2

Competing cumulative risks of clearance, progression (to CIN2 + ), and persistence of HPV-16/18 infections in the vaccine and control group. CIN2 + , cervical intraepithelial neoplasia grade 2 or greater; HR-HPV, high-risk human papillomavirus; FDR, false discovery rate. In competing risk analyses, the estimates for progression (to CIN2 + ), clearance, and persistence add up to 100% at each time point. A stratified Benjamini-Hochberg FDR procedure was used to adjust for multiple comparisons. All statistical tests were two-sided, with a significance level of α = 0.05.

Cumulative_Incidence_of_Clearance_and_Progression

clearance, progression (to CIN2+), and persistence

Fig. 2 · Panel Cumulative_Incidence_of_Clearance_and_Progression

failed 待 EXE 对齐 预期 4 条 已提取 0 条

Panel Cumulative_Incidence_of_Clearance_and_Progression 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 4 条,实际恢复 0 条曲线 1:off origin start曲线 1:extreme upward reversal曲线 2:off origin start
No curves extracted
查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Study profile. CIN2 + , cervical intraepithelial neoplasia grade 2 or greater; HR-HPV, high-risk human papillomavirus; 6mPI, persistent infections (over 6 months); 12mPI, persistent infections (over 12 months). Participants who were negative for the corresponding HPV type at day 0, as well as those who attended at least one follow-up visit, were included in the HPV incident infection analysis set. Among them, participants who had not completed colposcopy referral were excluded from the cervical lesion analysis set. Participants who were negative for the corresponding HPV type at day 0, and attended two follow-up visits at intervals of at least 150 days (300 days), were included in the 6mPI (12mPI) analysis set.
非 KM Figure
Fig. 3Competing cumulative risks of clearance, progression (to CIN2 + ), and persistence of HPV-52 infections in the vaccine and control group. CIN2 + , cervical intraepithelial neoplasia grade 2 or greater; HR-HPV, high-risk human papillomavirus; FDR false discovery rate. In competing risk analyses, the estimates for progression (to CIN2 + ), clearance, and persistence add up to 100% at each time point. A stratified Benjamini-Hochberg FDR procedure was used to adjust for multiple comparisons. All statistical tests were two-sided, with a significance level of α = 0.05.
非 KM Figure
Fig. 4Competing cumulative risks of clearance, progression (to CIN2 + ), and persistence of HPV-31/33/45 infections in the vaccine and control group. CIN2 + , cervical intraepithelial neoplasia grade 2 or greater; HR-HPV, high-risk human papillomavirus; FDR false discovery rate. In competing risk analyses, the estimates for progression (to CIN2 + ), clearance, and persistence add up to 100% at each time point. A stratified Benjamini-Hochberg FDR procedure was used to adjust for multiple comparisons. All statistical tests were two-sided, with a significance level of α = 0.05.
非 KM Figure